High dose intravenous iron: A note of caution

Nephrology Dialysis Transplantation

Volumn 17, Issue 6, 2002, Pages 962-965

  Kletzmayr, Josef ^a   Sunder Plassmann, Gere ^a   Hörl, Walter H ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

Chronic kidney disease; High dose intravenous iron; Toxicity

Indexed keywords

ALPHA TOCOPHEROL; ASCORBIC ACID; FERRIC HYDROXIDE SUCROSE; FERRITIN; IRON DEXTRAN; LOW DENSITY LIPOPROTEIN; MESSENGER RNA; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO; RECOMBINANT ERYTHROPOIETIN; IRON;

ACUTE HEART INFARCTION; ANAPHYLAXIS; ATHEROSCLEROSIS; BACTERIAL VIRULENCE; BRONCHOSPASM; CARDIOMYOPATHY; CARDIOTOXICITY; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DYSPNEA; EDITORIAL; FEMALE; GENETIC DISORDER; GENETIC SUSCEPTIBILITY; HEART FAILURE; HEMODIALYSIS; HOST RESISTANCE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; HYPOTENSION; IRON DEFICIENCY ANEMIA; IRON OVERLOAD; IRON THERAPY; KIDNEY FAILURE; MALE; PRIORITY JOURNAL; PRURITUS; VOMITING; ANEMIA; BLOOD; CHRONIC KIDNEY FAILURE; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY DISEASE; METABOLISM; PHYSIOLOGY;

ANEMIA; FERRITINS; HUMANS; INJECTIONS, INTRAVENOUS; IRON; KIDNEY DISEASES; KIDNEY FAILURE, CHRONIC; VITAMIN E;

EID: 0035991931     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/17.6.962     Document Type: Editorial

References (46)

1. A biochemical, histochemial and electron microscopic study on the effects of iron-loading on the hearts of mice
2. Iron-mediated cardiotoxicity develops independently of extracellular hydroxyl radicals in isolated rat hearts
3. Cardioprotective effects of alpha-tocopherol, ascorbate, deferoxamine, and deferiprone: Mitochondrial function in cultured, iron-loaded heart cells
4. Macrophages require both iron and copper to oxidize low-density lipoprotein in Hanks' balanced salt solution
5. Dietary iron concentration alters LDL oxidatively. The effect of antioxidants
6. Iron overload augments the development of atherosclerotic lesions in rabbits
7. Iron overload diminishes atherosclerosis in apoE-deficient mice
8. Colocalization of iron and ceroid in human atherosclerosis lesions
9. Decreased sodium and increased transient outward potassium currents in iron-loaded cardiac myocytes. Implications for the arrhythmogenesis of human siderotic heart disease
10. Body iron stores and the risk of carotid atherosclerosis: Prospective results from the Bruneck study
11. Association between body iron stores and the risk of acute myocardial infarction in men
12. Serum ferritin and risk of myocardial infarction in the elderly: The Rotterdam Study
13. Coronary heart disease and iron status. Meta-analyses of prospective studies
14. Iron status and the risk of coronary heart disease: An example of the use of nutritional epidemiology in chronic disease research
15. Inflammatory and atherosclerotic interactions in the depleted uremic patient
16. Iron therapy and cardiovascular disease
17. Cohort study of relation between donating blood and risk of myocardial infarction in 2682 men in eastern Finland
18. Possible association of a reduction in cardiovascular events with blood donation
19. Association body iron stores and the risk of acute myocardial infarction in men
20. Iron chelation improves endothelial function in patients with coronary artery disease
21. Hereditary haemochromatosis and the hypothesis that iron depletion protects against ischemic heart disease
22. Inherited disorders of iron metabolism
23. Heterozygosity for a hereditary hemochromatosis gene is associated with cardiovascular mortality in women
24. 282Tyr mutation: A prospective cohort study in men in eastern Finland
25. Iron and the genetics of cardiovascular disease
26. Serum ferritin and C282Y mutation of the hemochromatosisgene as predictors of asymptomatic carotid atherosclerosis in a community population
27. Association studies between haemochromatosis gene mutations and the risk of cardiovascular diseases
28. Prevalence of hereditary haemochromatosis in premature atherosclerotic vascular disease
29. Serum ferritin is a marker of morbidity and mortality in hemodialysis patients
30. Iron overload and cardiovascular complications in dialysis patients
31. Iron administration and clinical outcomes in hemodialysis patients
32. Vitamin E attenuates oxidative stress induced by intravenous iron in patients on hemodialysis
33. Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): Randomised placebo-controlled trial
34. Intravenous administration of iron in epoetin-treated haemodialysis patients-which drugs, which regimen?
35. Safety and efficacy of iron sucrose in patients sensitive to iron dextran: North American Clinical Trial
36. Parenteral iron therapy: Problems and possible solutions
37. Sodium ferric gluconate complex in sucrose: Safer intravenous iron therapy than iron dextran
38. Sodium ferric gluconate complex (Ferrlecit®): Prospective experience in 1122 hemodialysis patients
39. Experience with a large dose (500 mg) of intravenous iron dextran and iron saccharate in peritoneal dialysis patients
40. Intravenous iron sucrose: Establishing a safe dose
41. Iron status and iron supplementation in peritoneal dialysis patients
42. Neutrophil impairment associated with iron therapy in hemodialysis patients with functional iron deficiency
43. Iron, atherosclerosis and ischemic heart disease
44. The iron hypothesis: Does iron play a role in atherosclerosis?
45. Anemia and iron deficiency in long-term renal transplant patients
46. A randomized trial of iron deficiency testing strategies in hemodialysis patients